|Day's Range||0.0500 - 0.0500|
In the latest trading session, Johnson & Johnson (JNJ) closed at $154.37, marking a +0.01% move from the previous day.
InMode, Johnson & Johnson, Intuitive Surgical and GE HealthCare are included in this Analyst Blog.
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
If you're like Warren Buffett, you favor solid companies that perform over the long term -- and, at the same time, reward investors with passive income. Buffett has made his fortune -- and the fortune of others as Berkshire Hathaway chairman -- by sticking to that idea. Well, an opportunity is here for two Buffett favorites.
(Bloomberg) -- Kenvue Inc., the consumer health business that Johnson & Johnson spun off this month, will be eligible for ratings from a slew of major Wall Street banks next week, offering a chance to see how analysts are assessing initial public offerings amid the latest equities volatility and recession worries. Most Read from BloombergBiden, McCarthy Forge Debt Deal in Bid to Avert US DefaultWorld’s Richest Man Throws In Towel on Beverly Hills HotelKey Takeaways From Deal Biden, GOP Sealed to
Bristol Myers (BMY) obtains Fast Track Designation from the FDA for milvexian, which is being developed in collaboration with Johnson and Johnson's Janssen.
Many investors actively seek dividend stocks, and who can blame them? Choosing the right dividend stocks is arguably the best way to avoid this risk: Not all dividend stocks are created equal. With that said, let's turn our attention to two companies that are practically passive income machines and will likely continue rewarding shareholders with payout increases for a long time: Johnson & Johnson (NYSE: JNJ) and Apple (NASDAQ: AAPL).
CNBC's Jim Cramer predicts a booming bull market for medical devices, with positive earnings reports across the space. INMD, JNJ, ISRG and GEHC can emerge as potential winners.
When you think of Johnson & Johnson (NYSE: JNJ), you may think of shampoo and Band-Aids. In fact, J&J is in the process of spinning off that business into an entity called Kenvue. What is J&J's top revenue driver?
Key Insights The projected fair value for Johnson & Johnson is US$202 based on 2 Stage Free Cash Flow to Equity Johnson...
Johnson & Johnson (JNJ) closed the most recent trading day at $156.66, moving -0.1% from the previous trading session.
Medtronic (NYSE: MDT) and Johnson & Johnson (NYSE: JNJ) are perfect examples of this type of winning long-term investment. Medtronic sells devices worldwide related to diabetes, cardiovascular, neuroscience, and surgery. Thanks to its vast portfolio, Medtronic has increased earnings over time.
Johnson & Johnson has settled its lawsuit over Amgen Inc's proposed biosimilar version of J&J's top-selling treatment Stelara for psoriasis and other autoimmune conditions, according to a filing in Delaware federal court. Amgen said in a statement on Tuesday that the settlement terms are confidential, but it will allow the company to sell its biosimilar of Stelara "no later than January 1st, 2025."
(Reuters) -Johnson & Johnson has settled its lawsuit over Amgen Inc's proposed biosimilar version of J&J's top-selling treatment Stelara for psoriasis and other autoimmune conditions, according to a filing in Delaware federal court. Amgen said in a statement on Tuesday that the settlement terms are confidential, but it will allow the company to sell its biosimilar of Stelara "no later than January 1st, 2025." A J&J spokesperson said the company will "continue to defend the intellectual property associated with our medicines to protect our ability to innovate and develop life-changing therapies for patients."
Johnson & Johnson (NYSE: JNJ) and Dollar General (NYSE: DG) are traditionally strong, defensive stocks. Both companies deliver stable earnings, low volatility, and -- last but certainly not least -- dependable dividends. Johnson & Johnson stock traditionally has done well during downturns compared to the rest of the market.
It's hard to beat Warren Buffett's knack for making money, which is why so many investors keep a sharp eye on the stocks Buffett buys through his holding company, Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B). Of the nearly 50 stocks Buffett currently owns, here are five you might want to buy now and hold forever. Johnson & Johnson (NYSE: JNJ) is one of the longest-held stocks in Buffett's portfolio, and there are solid reasons you also might want to buy and hold this healthcare stock.
Here's why three Motley Fool contributors think that AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ) are relatively safe stocks to buy if a recession is declared this year. Prosper Junior Bakiny (AbbVie): It may be hard to believe that AbbVie is a safe stock right now.
With its listing on the New York Stock Exchange on May 4 and the conclusion of its initial public offering (IPO) on May 8, Kenvue (NYSE: KVUE) is finally a separate entity from Johnson & Johnson (NYSE: JNJ). The IPO raised net proceeds of $4.2 billion, and it marks the birth of a new giant within the consumer health products industry. In case you aren't familiar, Kenvue owns the rights to dozens of popular consumer health brands like Listerine, Aveeno, Tylenol, Motrin, Baby Powder, and even Band-Aids.
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The continued bear market in stocks has a silver lining. Johnson & Johnson (NYSE: JNJ) and Prologis (NYSE: PLD) are great stocks to double up on right now for those with a low allocation to these leading dividend payers. Meanwhile, investors who don't own them yet should consider adding them to their portfolio.
Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Johnson...
This makes every sizable downturn in equities a buying opportunity for patient investors. What's more, most online brokerages have completely done away with commission fees and minimum deposit requirements, which makes it easier than ever for everyday investors to put their money to work on Wall Street. The first stock that makes for a smart buy with the major stock indexes well off their all-time highs is Alphabet (NASDAQ: GOOGL)(NASDAQ: GOOG), the parent company of internet search engine Google, streaming platform YouTube, and autonomous vehicle company Waymo, among other subsidiaries.
If you're buying a dividend stock that's trading near its low for the year, it stands to reason that the yield is also higher than it would normally be. The tough part is ensuring you have found a quality stock. Three that qualify are Johnson & Johnson (NYSE: JNJ), Paychex (NASDAQ: PAYX), and Keurig Dr Pepper (NASDAQ: KDP).
The combination of AstraZeneca's cancer drug, Tagrisso, with chemotherapy to treat patients with a type of lung cancer showed positive results in a late-stage trial, the company said on Wednesday. The drug maker said patients on the combined treatment showed a meaningful improvement in progression-free survival, or how long a patient lives without the disease getting worse after treatment, than patients given only Tagrisso. The trial was on patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.